{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:43:08Z","timestamp":1787002988417,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-2022R1A2B5B03001431"],"award-info":[{"award-number":["NRF-2022R1A2B5B03001431"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ubiquitination serves a critical role in regulating both inflammatory responses and kidney injury. Among inherited renal disorders, autosomal dominant polycystic kidney disease (ADPKD) has demonstrated associations with disrupted ubiquitin signaling that exacerbates inflammation and cyst progression. In this study, we demonstrate that the E3 ligase Pellino1 (Peli1) acts as an essential contributor to the pathogenesis of ADPKD amid inflammatory conditions. In individuals with clear cell renal cell carcinoma (ccRCC), Peli1 exhibits markedly elevated expression, and this upregulation is associated with adverse clinical outcomes. Additionally, we find that various TLR stimulations in renal tubular cells induce increased Peli1 expression, which is also elevated in samples from ADPKD patients. Using doxycycline-inducible Peli1-transgenic mice, we establish that Peli1 overexpression leads to impaired renal function and facilitates cyst formation. On a mechanistic level, elevated Peli1 promotes cystic epithelial cell proliferation by activating mTOR signaling, accomplished through the stabilization of S6K1. In summary, our data indicate that TLR-driven upregulation of Peli1 facilitates renal cyst growth via S6K1 stabilization. These results reveal a novel mechanistic link between PKD and ccRCC.<\/jats:p>","DOI":"10.1038\/s41419-026-08479-6","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T04:04:42Z","timestamp":1772683482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pellino1-mTOR\/S6K1 signaling axis is a key pathogenesis for the development of polycystic kidney disease"],"prefix":"10.1038","volume":"17","author":[{"given":"Suhyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1433-5699","authenticated-orcid":false,"given":"Min-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Kyoung","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Mo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Mi","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heounjeong","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0954-8649","authenticated-orcid":false,"given":"Eun-Ji","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-1646","authenticated-orcid":false,"given":"Chang-Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"8479_CR1","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1681\/ASN.2018050493","volume":"29","author":"MB Lanktree","year":"2018","unstructured":"Lanktree MB, Haghighi A, Guiard E, Iliuta IA, Song X, Harris PC, et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol. 2018;29:2593\u20132600.","journal-title":"J Am Soc Nephrol"},{"key":"8479_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1681\/ASN.2017050483","volume":"29","author":"E Cornec-Le Gall","year":"2018","unstructured":"Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol. 2018;29:13\u201323.","journal-title":"J Am Soc Nephrol"},{"key":"8479_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4:50.","journal-title":"Nat Rev Dis Primers"},{"key":"8479_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1681\/ASN.2010030328","volume":"21","author":"PC Harris","year":"2010","unstructured":"Harris PC. What is the role of somatic mutation in autosomal dominant polycystic kidney disease? J Am Soc Nephrol. 2010;21:1073\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"8479_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4132\/KoreanJPathol.2012.46.4.382","volume":"46","author":"KY Na","year":"2012","unstructured":"Na KY, Kim HS, Park YK, Chang SG, Kim YW. Multifocal renal cell carcinoma of different histological subtypes in autosomal dominant polycystic kidney disease. Korean J Pathol. 2012;46:382\u20136.","journal-title":"Korean J Pathol"},{"key":"8479_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs\u2014Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93\u2013105.","journal-title":"Eur Urol"},{"key":"8479_CR7","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S1470-2045(16)30250-9","volume":"17","author":"TM Yu","year":"2016","unstructured":"Yu TM, Chuang YW, Yu MC, Chen CH, Yang CK, Huang ST, et al. Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study. Lancet Oncol. 2016;17:1419\u201325.","journal-title":"Lancet Oncol"},{"key":"8479_CR8","doi-asserted-by":"crossref","unstructured":"Millet-Boureima C, He S, Le TBU, Gamberi C. Modeling neoplastic growth in renal cell carcinoma and polycystic kidney disease. Int J Mol Sci. 2021;22:3918.","DOI":"10.3390\/ijms22083918"},{"key":"8479_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41581-019-0148-1","volume":"15","author":"C Meyer-Schwesinger","year":"2019","unstructured":"Meyer-Schwesinger C. The ubiquitin-proteasome system in kidney physiology and disease. Nat Rev Nephrol. 2019;15:393\u2013411.","journal-title":"Nat Rev Nephrol"},{"key":"8479_CR10","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1172\/JCI41531","volume":"120","author":"S Qin","year":"2010","unstructured":"Qin S, Taglienti M, Nauli SM, Contrino L, Takakura A, Zhou J, et al. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Investig. 2010;120:3617\u201328.","journal-title":"J Clin Investig"},{"key":"8479_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109648","volume":"72","author":"C Formica","year":"2020","unstructured":"Formica C, Peters DJM. Molecular pathways involved in injury-repair and ADPKD progression. Cell Signal. 2020;72:109648.","journal-title":"Cell Signal"},{"key":"8479_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06441","volume":"7","author":"R Habib","year":"2021","unstructured":"Habib R. Multifaceted roles of Toll-like receptors in acute kidney injury. Heliyon. 2021;7:e06441.","journal-title":"Heliyon"},{"key":"8479_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/kisup.2014.5","volume":"4","author":"WH Yiu","year":"2014","unstructured":"Yiu WH, Lin M, Tang SC. Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int Suppl. 2014;4:20\u201325.","journal-title":"Kidney Int Suppl"},{"key":"8479_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"D Li","year":"2021","unstructured":"Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6:291.","journal-title":"Signal Transduct Target Ther"},{"key":"8479_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1681\/ASN.2007090982","volume":"19","author":"B Zhang","year":"2008","unstructured":"Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol. 2008;19:923\u201332.","journal-title":"J Am Soc Nephrol"},{"key":"8479_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1681\/ASN.2009070722","volume":"21","author":"WP Pulskens","year":"2010","unstructured":"Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, et al. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol. 2010;21:1299\u2013308.","journal-title":"J Am Soc Nephrol"},{"key":"8479_CR17","doi-asserted-by":"publisher","first-page":"F143","DOI":"10.1152\/ajprenal.00398.2012","volume":"305","author":"H Mudaliar","year":"2013","unstructured":"Mudaliar H, Pollock C, Komala MG, Chadban S, Wu H, Panchapakesan U. The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. Am J Physiol Renal Physiol. 2013;305:F143\u201354.","journal-title":"Am J Physiol Renal Physiol"},{"key":"8479_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrneph.2010.16","volume":"6","author":"A Gluba","year":"2010","unstructured":"Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol. 2010;6:224\u201335.","journal-title":"Nat Rev Nephrol"},{"key":"8479_CR19","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.4049\/jimmunol.168.3.1286","volume":"168","author":"TG Wolfs","year":"2002","unstructured":"Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MA, Hiemstra PS, et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol. 2002;168:1286\u201393.","journal-title":"J Immunol"},{"key":"8479_CR20","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.4049\/jimmunol.169.4.2026","volume":"169","author":"N Tsuboi","year":"2002","unstructured":"Tsuboi N, Yoshikai Y, Matsuo S, Kikuchi T, Iwami K, Nagai Y, et al. Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells. J Immunol. 2002;169:2026\u201333.","journal-title":"J Immunol"},{"key":"8479_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/1744-9987.12458","volume":"20","author":"I Kocyigit","year":"2016","unstructured":"Kocyigit I, Sener EF, Taheri S, Eroglu E, Ozturk F, Unal A, et al. Toll-like receptors in the progression of autosomal dominant polycystic kidney disease. Ther Apher Dial. 2016;20:615\u201322.","journal-title":"Ther Apher Dial"},{"key":"8479_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/cmi.2011.60","volume":"9","author":"W Jin","year":"2012","unstructured":"Jin W, Chang M, Sun SC. Peli: a family of signal-responsive E3 ubiquitin ligases mediating TLR signaling and T-cell tolerance. Cell Mol Immunol. 2012;9:113\u201322.","journal-title":"Cell Mol Immunol"},{"key":"8479_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1292022","volume":"14","author":"L Yan","year":"2023","unstructured":"Yan L, Cui Y, Feng J. Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers. Front Immunol. 2023;14:1292022.","journal-title":"Front Immunol"},{"key":"8479_CR24","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s12276-020-00489-4","volume":"52","author":"S Kim","year":"2020","unstructured":"Kim S, Lee SY, Bae S, Lee JK, Hwang K, Go H, et al. Pellino1 promotes chronic inflammatory skin disease via keratinocyte hyperproliferation and induction of the T helper 17 response. Exp Mol Med. 2020;52:1537\u201349.","journal-title":"Exp Mol Med"},{"key":"8479_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/ni.1777","volume":"10","author":"M Chang","year":"2009","unstructured":"Chang M, Jin W, Sun SC. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol. 2009;10:1089\u201395.","journal-title":"Nat Immunol"},{"key":"8479_CR26","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104532","volume":"40","author":"CJ Ko","year":"2021","unstructured":"Ko CJ, Zhang L, Jie Z, Zhu L, Zhou X, Xie X, et al. The E3 ubiquitin ligase Peli1 regulates the metabolic actions of mTORC1 to suppress antitumor T cell responses. EMBO J. 2021;40:e104532.","journal-title":"EMBO J"},{"key":"8479_CR27","doi-asserted-by":"crossref","unstructured":"Panda DK, Bai X, Zhang Y, Stylianesis NA, Koromilas AE, Lipman ML, et al. SCF-SKP2 E3 ubiquitin ligase links mTORC1\/ER stress\/ISR with YAP activation in murine renal cystogenesis. J Clin Investig. 2022;132:e153943.","DOI":"10.1172\/JCI153943"},{"key":"8479_CR28","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1158\/0008-5472.CAN-20-3979","volume":"81","author":"H Wu","year":"2021","unstructured":"Wu H, He D, Biswas S, Shafiquzzaman M, Zhou X, Charron J, et al. mTOR activation initiates renal cell carcinoma development by coordinating ERK and p38MAPK. Cancer Res. 2021;81:3174\u201386.","journal-title":"Cancer Res"},{"key":"8479_CR29","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1038\/s41379-020-0607-z","volume":"33","author":"JM Roldan-Romero","year":"2020","unstructured":"Roldan-Romero JM, Santos M, Lanillos J, Caleiras E, Anguera G, Maroto P, et al. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. Mod Pathol. 2020;33:2580\u201390.","journal-title":"Mod Pathol"},{"key":"8479_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.12688\/f1000research.13179.1","volume":"7","author":"S Nabi","year":"2018","unstructured":"Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Research. 2018;7:307.","journal-title":"F1000Research"},{"key":"8479_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449\u201356.","journal-title":"Lancet"},{"key":"8479_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.molmed.2011.06.003","volume":"17","author":"O Ibraghimov-Beskrovnaya","year":"2011","unstructured":"Ibraghimov-Beskrovnaya O, Natoli TA. mTOR signaling in polycystic kidney disease. Trends Mol Med. 2011;17:625\u201333.","journal-title":"Trends Mol Med"},{"key":"8479_CR33","doi-asserted-by":"publisher","unstructured":"Ding W, Yousefi K, Shehadeh LA. Isolation, characterization, and high throughput extracellular flux analysis of mouse primary renal tubular epithelial cells. J Vis Exp. 2018;57718. https:\/\/doi.org\/10.3791\/57718.","DOI":"10.3791\/57718"},{"key":"8479_CR34","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1172\/JCI75667","volume":"124","author":"HY Park","year":"2014","unstructured":"Park HY, Go H, Song HR, Kim S, Ha GH, Jeon YK, et al. Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. J Clin Investig. 2014;124:4976\u201388.","journal-title":"J Clin Investig"},{"key":"8479_CR35","doi-asserted-by":"publisher","first-page":"e20071","DOI":"10.1097\/MD.0000000000020071","volume":"99","author":"KE Shim","year":"2020","unstructured":"Shim KE, Lee C, Kim JU, Choi GH, Kwak KM, Kim SH, et al. Comprehensive analysis of mutations of renal cell carcinoma in an autosomal dominant polycystic kidney disease patient. Medicine. 2020;99:e20071.","journal-title":"Medicine"},{"key":"8479_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.urology.2009.02.078","volume":"74","author":"P Hajj","year":"2009","unstructured":"Hajj P, Ferlicot S, Massoud W, Awad A, Hammoudi Y, Charpentier B, et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology. 2009;74:631\u20134.","journal-title":"Urology"},{"key":"8479_CR37","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/hmg\/ddp165","volume":"18","author":"X Song","year":"2009","unstructured":"Song X, Di Giovanni V, He N, Wang K, Ingram A, Rosenblum ND, et al. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet. 2009;18:2328\u201343.","journal-title":"Hum Mol Genet"},{"key":"8479_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111749","volume":"131","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Plansinis M, Peak S, Weber E, Wei A, Xu Y, et al. Activation of toll-like receptor 2 promotes the expression of inflammatory mediators and cell proliferation of human polycystic kidney disease cells. Cell Signal. 2025;131:111749.","journal-title":"Cell Signal"},{"key":"8479_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000516558","volume":"94","author":"DD Brown","year":"2021","unstructured":"Brown DD, Dauber A. Growth hormone and insulin-like growth factor dysregulation in pediatric chronic kidney disease. Horm Res Paediatr. 2021;94:105\u201314.","journal-title":"Horm Res Paediatr"},{"key":"8479_CR40","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/j.1651-2227.1995.tb13538.x","volume":"84","author":"M Konrad","year":"1995","unstructured":"Konrad M, Zerres K, Wuhl E, Rudnik-Schoneborn S, Holtkamp U, Scharer K. Body growth in children with polycystic kidney disease. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Acta Paediatr. 1995;84:1227\u201332.","journal-title":"Acta Paediatr"},{"key":"8479_CR41","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1081\/JDI-100104713","volume":"23","author":"R Rabkin","year":"2001","unstructured":"Rabkin R. Growth factor insensitivity in renal failure. Ren Fail. 2001;23:291\u2013300.","journal-title":"Ren Fail"},{"key":"8479_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1651-2227.1996.tb14056.x","volume":"85","author":"K Zerres","year":"1996","unstructured":"Zerres K, Rudnik-Schoneborn S, Deget F, Holtkamp U, Brodehl J, Geisert J, et al. Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft fur Padiatrische, Nephrologie. Acta Paediatr. 1996;85:437\u201345.","journal-title":"Acta Paediatr"},{"key":"8479_CR43","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.urology.2009.04.013","volume":"75","author":"SM Flechner","year":"2010","unstructured":"Flechner SM. Re: Hajj et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure (Urology 2010;74:631-4). Urology. 2010;75:752\u20133.","journal-title":"Urology"},{"key":"8479_CR44","doi-asserted-by":"publisher","first-page":"E1624","DOI":"10.1073\/pnas.1419502112","volume":"112","author":"H Hasumi","year":"2015","unstructured":"Hasumi H, Baba M, Hasumi Y, Lang M, Huang Y, Oh HF, et al. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proc Natl Acad Sci USA. 2015;112:E1624\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8479_CR45","first-page":"1051","volume":"142","author":"DL Schaffner","year":"1993","unstructured":"Schaffner DL, Barrios R, Massey C, Banez EI, Ou CN, Rajagopalan S, et al. Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol. 1993;142:1051\u201360.","journal-title":"Am J Pathol"},{"key":"8479_CR46","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/ndt\/gfu046","volume":"29","author":"V Cantaluppi","year":"2014","unstructured":"Cantaluppi V, Quercia AD, Dellepiane S, Ferrario S, Camussi G, Biancone L. Interaction between systemic inflammation and renal tubular epithelial cells. Nephrol Dial Transplant. 2014;29:2004\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"8479_CR47","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274\u201393.","journal-title":"Cell"},{"key":"8479_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.636037","volume":"9","author":"S Faes","year":"2021","unstructured":"Faes S, Demartines N, Dormond O. Mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives. Front Cell Dev Biol. 2021;9:636037.","journal-title":"Front Cell Dev Biol"},{"key":"8479_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.109468","volume":"66","author":"JP Margaria","year":"2020","unstructured":"Margaria JP, Campa CC, De Santis MC, Hirsch E, Franco I. The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: a complex interaction with polycystins and primary cilium. Cell Signal. 2020;66:109468.","journal-title":"Cell Signal"},{"key":"8479_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nri3599","volume":"14","author":"PN Moynagh","year":"2014","unstructured":"Moynagh PN. The roles of Pellino E3 ubiquitin ligases in immunity. Nat Rev Immunol. 2014;14:122\u201331.","journal-title":"Nat Rev Immunol"},{"key":"8479_CR51","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1097\/01.ASN.0000029587.47950.25","volume":"13","author":"BK Yoder","year":"2002","unstructured":"Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol. 2002;13:2508\u201316.","journal-title":"J Am Soc Nephrol"},{"key":"8479_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/bbrc.2001.4554","volume":"282","author":"PM Vassilev","year":"2001","unstructured":"Vassilev PM, Guo L, Chen XZ, Segal Y, Peng JB, Basora N, et al. Polycystin-2 is a novel cation channel implicated in defective intracellular Ca(2+) homeostasis in polycystic kidney disease. Biochem Biophys Res Commun. 2001;282:341\u201350.","journal-title":"Biochem Biophys Res Commun"},{"key":"8479_CR53","doi-asserted-by":"crossref","unstructured":"Al-Orjani Q, Alshriem LA, Gallagher G, Buqaileh R, Azizi N, AbouAlaiwi W. Mechanistic insights into the pathogenesis of polycystic kidney disease. Cells. 2025;14:1203.","DOI":"10.3390\/cells14151203"},{"key":"8479_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev.med.59.061206.112455","volume":"59","author":"S Garantziotis","year":"2008","unstructured":"Garantziotis S, Hollingsworth JW, Zaas AK, Schwartz DA. The effect of toll-like receptors and toll-like receptor genetics in human disease. Annu Rev Med. 2008;59:343\u201359.","journal-title":"Annu Rev Med"},{"key":"8479_CR55","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2174\/138920212803759712","volume":"13","author":"YT Lin","year":"2012","unstructured":"Lin YT, Verma A, Hodgkinson CP. Toll-like receptors and human disease: lessons from single nucleotide polymorphisms. Curr Genom. 2012;13:633\u201345.","journal-title":"Curr Genom"},{"key":"8479_CR56","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.1158\/1078-0432.CCR-07-0603","volume":"13","author":"T Morikawa","year":"2007","unstructured":"Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, et al. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:5703\u20139.","journal-title":"Clin Cancer Res"},{"key":"8479_CR57","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/jca.84502","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang S, Lu Y, Xia D, Liu Y. TLR4 predicts patient prognosis and immunotherapy efficacy in clear cell renal cell carcinoma. J Cancer. 2023;14:2181\u201397.","journal-title":"J Cancer"},{"key":"8479_CR58","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1002\/cam4.2983","volume":"9","author":"J Luo","year":"2020","unstructured":"Luo J, Xie Y, Zheng Y, Wang C, Qi F, Hu J, et al. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm. Cancer Med. 2020;9:4310\u201323.","journal-title":"Cancer Med"},{"key":"8479_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3892\/etm.2013.1392","volume":"7","author":"Z Zeng","year":"2014","unstructured":"Zeng Z, Que T, Zhang J, Hu Y. A study exploring critical pathways in clear cell renal cell carcinoma. Exp Ther Med. 2014;7:121\u201330.","journal-title":"Exp Ther Med"},{"key":"8479_CR60","doi-asserted-by":"publisher","first-page":"19218","DOI":"10.1074\/jbc.M115.640128","volume":"290","author":"M Murphy","year":"2015","unstructured":"Murphy M, Xiong Y, Pattabiraman G, Qiu F, Medvedev AE. Pellino-1 positively regulates toll-like receptor (TLR) 2 and TLR4 signaling and is suppressed upon induction of endotoxin tolerance. J Biol Chem. 2015;290:19218\u201332.","journal-title":"J Biol Chem"},{"key":"8479_CR61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ad.2016.05.009","volume":"107","author":"E Gonzalez-Parra","year":"2016","unstructured":"Gonzalez-Parra E, Dauden E, Carrascosa JM, Olveira A, Botella R, Bonanad C, et al. Kidney disease and psoriasis. a new comorbidity? Actas Dermosifiliogr. 2016;107:823\u20139.","journal-title":"Actas Dermosifiliogr"},{"key":"8479_CR62","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/ni.2090","volume":"12","author":"M Chang","year":"2011","unstructured":"Chang M, Jin W, Chang JH, Xiao Y, Brittain GC, Yu J, et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol. 2011;12:1002\u20139.","journal-title":"Nat Immunol"},{"key":"8479_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09641-9","volume":"10","author":"GH Ha","year":"2019","unstructured":"Ha GH, Ji JH, Chae S, Park J, Kim S, Lee JK, et al. Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks. Nat Commun. 2019;10:1577.","journal-title":"Nat Commun"},{"key":"8479_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2009040421","volume":"21","author":"JM Shillingford","year":"2010","unstructured":"Shillingford JM, Piontek KB, Germino GG, Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol. 2010;21:489\u201397.","journal-title":"J Am Soc Nephrol"},{"key":"8479_CR65","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P, King JD Jr., Li H, Zhang L, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA. 2011;108:2462\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8479_CR66","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nm.2171","volume":"16","author":"TA Natoli","year":"2010","unstructured":"Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. 2010;16:788\u201392.","journal-title":"Nat Med"},{"key":"8479_CR67","doi-asserted-by":"crossref","unstructured":"Torra R. Recent advances in the clinical management of autosomal dominant polycystic kidney disease. F1000Res. 2019;8:F1000 Faculty Rev-116.","DOI":"10.12688\/f1000research.17109.1"},{"key":"8479_CR68","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ctrv.2017.08.010","volume":"60","author":"A Sanchez-Gastaldo","year":"2017","unstructured":"Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat Rev. 2017;60:77\u201389.","journal-title":"Cancer Treat Rev"},{"key":"8479_CR69","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2217\/thy.11.32","volume":"8","author":"C Battelli","year":"2011","unstructured":"Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy. 2011;8:359\u201367.","journal-title":"Therapy"},{"key":"8479_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34255-z","volume":"13","author":"Y Muto","year":"2022","unstructured":"Muto Y, Dixon EE, Yoshimura Y, Wu H, Omachi K, Ledru N, et al. Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis. Nat Commun. 2022;13:6497.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08479-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:02:24Z","timestamp":1774987344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08479-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8479"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08479-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}